Nuformix plc (LSE:NFX) has unveiled an underwritten Open Offer to raise approximately £228,081 through the issuance of 114,040,535 Open Offer Shares at an Issue Price of 0.2p per share. CMC Markets UK Plc will underwrite the offer, ensuring full subscription.
The fundraising aims to give all qualifying shareholders an opportunity to participate while providing Nuformix with capital to advance its drug repurposing strategy. The company plans to use the proceeds to accelerate the development of new product opportunities in fibrosis and oncology—two therapeutic areas with significant unmet medical needs. These initiatives could strengthen its market position and create early-stage licensing opportunities.
Despite these strategic steps, Nuformix continues to face serious financial headwinds, including limited revenue generation and ongoing losses. While recent corporate progress and improving technical momentum are encouraging, they remain overshadowed by persistent financial instability and weak valuation metrics.
More about Nuformix plc
Nuformix plc is a pharmaceutical development company focused on drug repurposing to address unmet needs in fibrosis and oncology. By discovering and patenting new forms of existing drugs with improved physical properties, the company aims to develop differentiated, commercially attractive therapies with strong licensing potential.
Leave a Reply